Microbiology & Immunology

Projects

Projects per year 1985 2004 2008 2010 2011 2012 2014 2015 2016 2017 2018 2019 2025

• 17 Active
• 289 Finished

Projects per year

Search results

• Finished

  A New Immune Checkpoint Pathway in Human Bladder Cancer

  Zang, X.

  12/1/22 → 11/30/23

  Project: Research project

  • Urinary Bladder Neoplasms 100%
  • Immunotherapy 16%
  • Urologists 10%
  • Translational Medical Research 10%
  • Oncologists 10%

• Comprehensive genetic dissection of poxvirus membrane assembly and function

  Chandran, K.

  12/1/22 → 11/30/23

  Project: Research project

  • Orthopoxvirus 100%
  • Virion 77%
  • Poxviridae 67%
  • losigame 48%
  • Viruses 43%

• Identification of new inhibitors of essential functions in M. tuberculosis by high-throughput metabolic profiling

  Berney, M.

  11/18/22 → 10/31/23

  Project: Research project

  • Pharmaceutical Preparations 100%
  • Gene Knockdown Techniques 90%
  • Tuberculosis 85%
  • Libraries 61%
  • Molecular Sequence Annotation 45%

• Prometastatic Effects of Neoadjuvant Chemotherapy in Breast Cancer

  Karagiannis, G.

  9/14/22 → 8/31/23

  Project: Research project

• Coenzyme F420, helping mycobacteria find a niche in humans

  Berney, M.

  7/15/22 → 6/30/23

  Project: Research project

  • tuberculosis 100%
  • granuloma 43%
  • anaerobic conditions 35%
  • coenzymes 20%
  • Mycobacterium 19%

• The Biology of Lung Metastasis in Breast Cancer

  Backer, J. M., Bresnick, A. A. R., Entenberg, D. R., Oktay, M. H., Porcelli, S. A. & Guo, W.

  7/5/22 → 6/30/23

  Project: Research project

  • Lung 100%
  • Breast Neoplasms 99%
  • Epithelial-Mesenchymal Transition 96%
  • Neoplasm Metastasis 96%
  • Stromal Cells 62%

• Flow Cytometery and Cell Sorting Core

  Porcelli, S. A.

  6/1/22 → 5/31/23

  Project: Research project

  • Flow cytometry 100%
  • Sorting 52%
  • Cells 38%
  • Personnel 30%
  • Lead 24%

• Genetic engineering of Mycobacterium leprae to Glow and Grow

  Jacobs Jr., W. R.

  National Institute of Allergy and Infectious Diseases

  5/20/22 → 4/30/23

  Project: Research project

  • Mycobacterium leprae 100%
  • genetic engineering 42%
  • tuberculosis 24%
  • Bacilli 23%
  • plasmids 16%

• Viral and host determinants of susceptibility of diverse hantaviruses

  Jangra, R. & Jangra, R. R. K.

  National Institute of Allergy and Infectious Diseases

  6/1/21 → 5/31/23

  Project: Research project

  • Hantavirus 100%
  • Permissiveness 9%
  • Virion 6%
  • Glycoproteins 5%
  • Shrews 5%

• Optimizing SARS-CoV-2 wastewater based surveillance in urban and university campus settings.

  Chandran, K.

  1/1/21 → 12/31/21

  Project: Research project

  • Waste Water 100%
  • SARS Virus 44%
  • Disease Outbreaks 11%
  • Coronavirus 10%
  • Microfluidics 10%

• Optimizing SARS-CoV-2 wastewater based surveillance in urban and university campus settings.

  Uhlemann, A. C. & Chandran, K.

  National Institute on Drug Abuse

  1/1/21 → 5/31/23

  Project: Research project

  • Waste Water 100%
  • SARS Virus 78%
  • Disease Outbreaks 12%
  • Coronavirus 11%
  • Microfluidics 8%

• TB Phage therapy: Optimizing delivery methods of mycobacteriophages to target intracellular Mycobacterium tuberculosis

  Jacobs Jr., W. R.

  12/7/20 → 11/30/21

  Project: Research project

  • Mycobacteriophages 100%
  • Mycobacterium tuberculosis 38%
  • Tuberculosis 32%
  • Phage Therapy 20%
  • Mycobacterium smegmatis 9%

• TB Phage therapy: Optimizing delivery methods of mycobacteriophages to target intracellular Mycobacterium tuberculosis

  Jacobs Jr., W. R.

  National Institute of Allergy and Infectious Diseases

  12/7/20 → 11/30/22

  Project: Research project

  • Mycobacteriophages 100%
  • Phage Therapy 70%
  • Mycobacterium tuberculosis 57%
  • Drug Therapy 23%
  • Tuberculosis 16%

• CCL2-CCR2b signaling in HIV-1 fitness and disease; Role of host genetic polymorphisms

  Prasad, V. R.

  7/1/20 → 5/31/22

  Project: Research project

  • HIV-1 100%
  • Endosomal Sorting Complexes Required for Transport 70%
  • Actins 48%
  • HIV 47%
  • Viruses 46%

• Structure-based Vaccine Design for CCHFV

  Chandran, K.

  6/25/20 → 5/31/22

  Project: Research project

  • Crimean-Congo hemorrhagic fever virus 100%
  • National Institute of Allergy and Infectious Diseases (U.S.) 27%
  • Glycoproteins 23%
  • Ticks 21%
  • Vaccines 20%

• Einstein Mount Sinai Diabetes Research Center

  DiLorenzo, T. P. & Dilorenzo, T. T. P.

  National Institute of Diabetes and Digestive and Kidney Diseases

  4/1/20 → 3/31/24

  Project: Research project

  • chronic illness 100%
  • Technology 33%
  • infrastructure 14%
  • Research Personnel 12%
  • financial investment 9%

• Maximizing transfusion efficacy through nitric oxide enhancement strategies

  Friedman, J. M. & Intaglietta, M.

  National Heart, Lung, and Blood Institute

  9/20/19 → 8/31/21

  Project: Research project

  • blood transfusion 100%
  • nitric oxide 66%
  • anemia 38%
  • blood viscosity 30%
  • blood flow 27%

• Development of a nanotechnology resource center to advance urological research

  Friedman, J. M.

  National Institute of Diabetes and Digestive and Kidney Diseases

  9/17/19 → 6/30/21

  Project: Research project

  • nanoparticles 100%
  • nanotechnology 96%
  • research projects 78%
  • synthesis 12%
  • cooperative research 10%

• Development of a nanotechnology resource center to advance urological research

  Davies, K. & Friedman, J. M.

  National Institute of Diabetes and Digestive and Kidney Diseases

  9/17/19 → 6/30/21

  Project: Research project

  • Nanotechnology 100%
  • Nanoparticles 71%
  • Research Personnel 18%
  • Urologic Diseases 12%
  • Resource Allocation 10%

• Prometastatic Effects of Neoadjuvant Chemotherapy in Breast Cancer

  Karagiannis, G.

  National Cancer Institute

  9/16/19 → 8/31/21

  Project: Research project

  • Breast Neoplasms 100%
  • Drug Therapy 95%
  • Neoplasm Metastasis 70%
  • Neoplasms 64%
  • Macrophages 59%

• Regulation of SAMHD1 antiviral activity

  Diaz-Griffero, F.

  9/1/19 → 6/30/22

  Project: Research project

  • Antiviral Agents 100%
  • HIV-2 75%
  • Phosphorylation 60%
  • Dendritic Cells 52%
  • Reverse Transcription 51%

• Cytek Aurora Multiparameter Flow Cytometer

  Porcelli, S. A.

  8/1/19 → 7/31/20

  Project: Research project

  • Flow cytometry 100%
  • Fluorescence 38%
  • Dyes 37%
  • Semiconductor detectors 29%
  • Fluorophores 27%

• Cytek Aurora Multiparameter Flow Cytometer

  Porcelli, S. A.

  NIH Office of the Director

  8/1/19 → 7/31/20

  Project: Research project

  • Flow cytometry 100%
  • Fluorescence 38%
  • Dyes 37%
  • Semiconductor detectors 29%
  • Fluorophores 27%

• FACS (Flow Cytometry)

  Porcelli, S. A. & Porcelli, S. A.

  National Cancer Institute

  7/1/19 → 6/30/22

  Project: Research project

  • flow cytometry 100%
  • neoplasms 79%
  • sorting 44%
  • cells 28%
  • biosafety 19%

• NIH Support for Conferences and Scientific Meetings

  Larsen, M. H.

  3/1/19 → 2/29/20

  Project: Research project

  • Mycobacterium 100%
  • mycobacterial diseases 86%
  • leprosy 41%
  • tuberculosis 34%
  • researchers 24%

• NIH Support for Conferences and Scientific Meetings

  Larsen, M. H.

  National Institute of Allergy and Infectious Diseases

  3/1/19 → 2/29/20

  Project: Research project

  • Mycobacterium 100%
  • mycobacterial diseases 86%
  • leprosy 41%
  • tuberculosis 34%
  • researchers 24%

• Core B: Industrialization Core

  Chandran, K. & Chandran, K.

  National Institute of Allergy and Infectious Diseases

  3/1/19 → 1/31/24

  Project: Research project

  • Industrial Development 100%
  • Monoclonal Antibodies 34%
  • Survivors 27%
  • Technology 20%
  • Glycosylation 16%

• In Vivo Efficacy Testing Core

  Chandran, K. & Chandran, K.

  National Institute of Allergy and Infectious Diseases

  3/1/19 → 1/31/24

  Project: Research project

  • Hantavirus 100%
  • Nairovirus 67%
  • Lead 64%
  • Ebolavirus 63%
  • Rodent Diseases 62%

• Project II: Biologics Engineering and Antibody Mechanism of Action

  Chandran, K. & Chandran, K.

  National Institute of Allergy and Infectious Diseases

  3/1/19 → 1/31/24

  Project: Research project

  • Biological Products 100%
  • Medical Countermeasures 78%
  • Ebolavirus 65%
  • Monoclonal Antibodies 59%
  • Antibodies 54%

• Project I: Discovery and Evaluation of Antibodies and Cocktails

  Chandran, K. & Chandran, K.

  National Institute of Allergy and Infectious Diseases

  3/1/19 → 1/31/24

  Project: Research project

  • Hantavirus 100%
  • Monoclonal Antibodies 85%
  • Sin Nombre virus 80%
  • Viruses 63%
  • Antibodies 57%

• Core A: Administrative Core

  Chandran, K. & Chandran, K.

  National Institute of Allergy and Infectious Diseases

  3/1/19 → 1/31/24

  Project: Research project

  • Hantavirus 100%
  • Intellectual Property 72%
  • Nairovirus 42%
  • Sin Nombre virus 40%
  • Zoonoses 25%

• Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral Threats

  Chandran, K.

  2/14/19 → 1/31/22

  Project: Research project

  • Hantavirus 100%
  • Sin Nombre virus 73%
  • Crimean-Congo hemorrhagic fever virus 66%
  • Antibodies 31%
  • Nairovirus 25%

• Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral Threats

  Chandran, K.

  National Institute of Allergy and Infectious Diseases

  2/14/19 → 1/31/24

  Project: Research project

  • Hantavirus 100%
  • Human Development 75%
  • Crimean-Congo hemorrhagic fever virus 69%
  • Sin Nombre virus 68%
  • Antibodies 42%

• Eradicating persistent M. tuberculosis by synthetic lethality of terminal respiratory oxidases

  Berney, M.

  11/13/18 → 10/31/21

  Project: Research project

  • Tuberculosis 100%
  • Mycobacterium tuberculosis 94%
  • 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidin-1-yl)benzyl) imidazo(1,2-a)pyridine-3-carboxamide 79%
  • Cytochromes 69%
  • Electron Transport Complex IV 57%

• Eradicating persistent M. tuberculosis by synthetic lethality of terminal respiratory oxidases

  Berney, M.

  National Institute of Allergy and Infectious Diseases

  11/13/18 → 10/31/23

  Project: Research project

  • Synthetic Lethal Mutations 100%
  • Tuberculosis 64%
  • Oxidoreductases 63%
  • Cytochromes 48%
  • 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidin-1-yl)benzyl) imidazo(1,2-a)pyridine-3-carboxamide 45%

• An immunotherapeutic strategy for the induction and stabilization of remission in type 1 diabetes

  DiLorenzo, T. P. & DiLorenzo, T. P.

  9/15/18 → 7/31/21

  Project: Research project

  • T-Lymphocytes 100%
  • Remission Induction 63%
  • Type 1 Diabetes Mellitus 57%
  • Antigens 51%
  • Immunological Synapses 48%

• An immunotherapeutic strategy for the induction and stabilization of remission in type 1 diabetes

  DiLorenzo, T. P. & Almo, S. C.

  National Institute of Diabetes and Digestive and Kidney Diseases

  9/15/18 → 7/31/21

  Project: Research project

  • Remission Induction 100%
  • Type 1 Diabetes Mellitus 70%
  • T-Lymphocytes 55%
  • Antigens 28%
  • Immunological Synapses 26%

• The Study of Human Sulfuryl-Transfer Biology

  Leyh, T. S.

  9/8/18 → 8/31/21

  Project: Research project

  • Sulfotransferases 100%
  • monoamine-sulfating phenol sulfotransferase 29%
  • sapropterin 21%
  • Libraries 21%
  • Neurotransmitter Agents 20%

• The Study of Human Sulfuryl-Transfer Biology

  Leyh, T. S.

  National Institute of General Medical Sciences

  9/8/18 → 8/31/23

  Project: Research project

  • Sulfotransferases 100%
  • monoamine-sulfating phenol sulfotransferase 29%
  • Neurotransmitter Agents 20%
  • Libraries 20%
  • Protein Isoforms 19%

• Shortening Tuberculosis Chemotherapies using N-acetylcysteine

  Jacobs Jr., W. R.

  6/15/18 → 5/31/20

  Project: Research project

  • Acetylcysteine 100%
  • Tuberculosis 89%
  • Mycobacterium tuberculosis 86%
  • Pharmaceutical Preparations 44%
  • Multidrug-Resistant Tuberculosis 35%

• Shortening Tuberculosis Chemotherapies using N-acetylcysteine

  Jacobs Jr., W. R.

  National Institute of Allergy and Infectious Diseases

  6/15/18 → 5/31/20

  Project: Research project

  • Acetylcysteine 100%
  • Tuberculosis 77%
  • Mycobacterium tuberculosis 75%
  • Drug Therapy 42%
  • Pharmaceutical Preparations 39%

• Rapid screening for modes-of-action of M. tuberculosis inhibitors by high-throughput metabolic fingerprinting

  Berney, M.

  National Institute of Allergy and Infectious Diseases

  6/11/18 → 5/31/21

  Project: Research project

  • Drug Discovery 100%
  • Mycobacterium tuberculosis 94%
  • Tuberculosis 73%
  • Libraries 57%
  • Genome 43%

• Rapid screening for modes-of-action of M. tuberculosis inhibitors by high-throughput metabolic fingerprinting

  Berney, M.

  6/11/18 → 5/31/21

  Project: Research project

  • Drug Discovery 100%
  • Mycobacterium tuberculosis 94%
  • Libraries 57%
  • Tuberculosis 53%
  • Genome 43%

• Immunoregulation by indoleamine 2,3-dioxygenases in tuberculosis

  Porcelli, S. A., Chan, J. & Porcelli, S. A.

  5/1/18 → 4/30/22

  Project: Research project

  • Indoleamine-Pyrrole 2,3,-Dioxygenase 100%
  • Protein Isoforms 27%
  • Tuberculosis 24%
  • Immunosuppressive Agents 20%
  • Kynurenine 19%

• Immunoregulation by indoleamine 2,3-dioxygenases in tuberculosis

  Chan, J., Porcelli, S. A., Chan, J. J. R. & Porcelli, S. S. A.

  National Institute of Allergy and Infectious Diseases

  5/1/18 → 4/30/23

  Project: Research project

  • Indoleamine-Pyrrole 2,3,-Dioxygenase 100%
  • Tuberculosis 64%
  • Protein Isoforms 36%
  • Immunosuppressive Agents 23%
  • Kynurenine 19%

• Structural, functional, and mechanistic anlaysis of autoreactive CD8 T cells

  DiLorenzo, T. P.

  2/8/18 → 1/31/22

  Project: Research project

  • T-Lymphocytes 100%
  • Alleles 59%
  • T-Cell Antigen Receptor 41%
  • Peptides 38%
  • Type 1 Diabetes Mellitus 36%

• Structural, functional, and mechanistic anlaysis of autoreactive CD8 T cells

  DiLorenzo, T. P. & Almo, S. C.

  National Institute of Allergy and Infectious Diseases

  2/8/18 → 1/31/23

  Project: Research project

  • T-Lymphocytes 100%
  • Alleles 48%
  • Type 1 Diabetes Mellitus 37%
  • T-Cell Antigen Receptor 33%
  • Peptides 31%

• Defining Novel Cellular Correlates of Protection Against Human Malaria by CyTOF

  Lauvau, G.

  National Institute of Allergy and Infectious Diseases

  2/6/18 → 1/31/21

  Project: Research project

  • Malaria 100%
  • Parasites 62%
  • Immunity 48%
  • T-Lymphocytes 37%
  • Antibody Formation 26%

• Defining Novel Cellular Correlates of Protection Against Human Malaria by CyTOF

  Lauvau, G.

  2/6/18 → 1/31/21

  Project: Research project

  • Malaria 100%
  • Parasites 56%
  • Immunity 44%
  • T-Lymphocytes 33%
  • Antibody Formation 24%

• Targeting mycobacterial ribosomes as a new approach to tuberculosis vaccines

  Porcelli, S. A.

  1/1/18 → 12/31/20

  Project: Research project

  • Tuberculosis Vaccines 100%
  • Mycobacterium bovis 56%
  • Mycobacterium tuberculosis 50%
  • BCG Vaccine 47%
  • Antigens 44%